A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Trial Profile

A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs LY 3002813 (Primary) ; LY 3002813 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Jul 2017.
    • 21 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Jul 2017.
    • 25 May 2017 Planned End Date changed from 28 Apr 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top